Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   intercloud--icld

Amerikaanse aandelen« Terug naar discussie overzicht

intercloud--icld

Volgen
429 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 22 »» | Laatste | Omlaag ↓
  7. [verwijderd] 19 januari 2016 20:29
    Guggenheim reissued their buy rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in a report released on Thursday morning, Analyst Ratings Network.com reports. The brokerage currently has a $195.00 price objective on the specialty pharmaceutical company’s stock.
    Other equities analysts also recently issued reports about the company. RBC Capital reduced their price target on Valeant Pharmaceuticals Intl from $206.00 to $194.00 and set an outperform rating for the company in a report on Monday, December 14th. Evercore ISI restated a buy rating on shares of Valeant Pharmaceuticals Intl in a report on Monday, October 19th. Jefferies Group reduced their price target on Valeant Pharmaceuticals Intl from $294.00 to $224.00 and set a buy rating for the company in a report on Tuesday, October 20th. Vetr upgraded Valeant Pharmaceuticals Intl from a buy rating to a strong-buy rating and set a $122.73 price target for the company in a report on Tuesday, December 29th. Finally, Stifel Nicolaus restated a buy rating and set a $285.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Sunday, November 1st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Valeant Pharmaceuticals Intl presently has an average rating of Buy and a consensus price target of $156.47.
    In related news, Director Ronald Harold Farmer bought 1,500 shares of the business’s stock in a transaction dated Wednesday, October 21st. The shares were purchased at an average price of $181.60 per share, with a total value of $272,400.00. Following the transaction, the director now owns 15,532 shares in the company, valued at approximately $2,820,611.20. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
    Other institutional investors have bought and sold shares of the company. Raymond James Trust boosted its position in Valeant Pharmaceuticals Intl by 1.0% in the fourth quarter. Raymond James Trust now owns 2,515 shares of the specialty pharmaceutical company’s stock worth $256,000 after buying an additional 24 shares during the last quarter. Acadian Asset Management boosted its position in Valeant Pharmaceuticals Intl by 31.8% in the fourth quarter. Acadian Asset Management now owns 2,900 shares of the specialty pharmaceutical company’s stock worth $293,000 after buying an additional 700 shares during the last quarter. Capstone Asset Management Company boosted its position in Valeant Pharmaceuticals Intl by 2.0% in the fourth quarter. Capstone Asset Management Company now owns 41,397 shares of the specialty pharmaceutical company’s stock worth $4,208,000 after buying an additional 813 shares during the last quarter. Jennison Associates boosted its position in Valeant Pharmaceuticals Intl by 0.8% in the third quarter. Jennison Associates now owns 308,200 shares of the specialty pharmaceutical company’s stock worth $54,977,000 after buying an additional 2,364 shares during the last quarter. Finally, Meag Munich Ergo Kapitalanlagegesellschaft boosted its position in Valeant Pharmaceuticals Intl by 6.6% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 73,800 shares of the specialty pharmaceutical company’s stock worth $12,732,000 after buying an additional 4,600 shares during the last quarter.
    Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 88.70 on Thursday. Valeant Pharmaceuticals Intl has a 12-month low of $69.33 and a 12-month high of $263.81. The firm’s 50-day moving average is $98.82 and its 200 day moving average is $167.46. The stock has a market capitalization of $30.43 billion and a P/E ratio of 50.95.
    Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.
  11. [verwijderd] 20 januari 2016 19:49

    More Bad News for Valeant Pharmaceuticals Intl Inc.

    By Benjamin Sinclair - January 20, 2016 | More on: VRX VRX

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) interim CEO Howard Schiller will be testifying in front of a U.S. congressional panel next week. The focus of his testimony will be the severe price hikes on two drugs, Isuprel and Nitropress.

    So what exactly does this mean for Valeant and its shareholders?

    The drugs in question

    Valeant acquired Isuprel and Nitropress, both of which are used to treat heart attacks, in February of last year. Then it immediately hiked the price of the drugs by 212% and 525% respectively, according to The Wall Street Journal. At the time, a Valeant spokeswoman stated bluntly that the company’s goal was to “maximize the value” of every drug to the company’s shareholders.

    Politics are working against Valeant

    Congress was not amused and requested information from Valeant about the revenue, costs, and expenses for these drugs.

    Things got a whole lot worse in September when biotech entrepreneur Martin Shkreli acquired the rights to Daraprim (a drug used to treat toxoplasmosis, a life-threatening parasitic infection) and then raised the drug’s price by 5,000%. Mr. Shkreli’s actions angered a lot of people and even drew a quick response from Hillary Clinton. All of a sudden, the spotlight was squarely on drug-price increases, and Valeant was caught up in the mix.

    To put it bluntly, Mr. Shkreli has effectively poisoned the well for Valeant. Even PhRMA, which lobbies on behalf of pharmaceutical companies, has felt compelled to distance itself from the two. So it cannot be good news that Mr. Shkreli will also be testifying at the same hearing.

    Granted, you can never count on Washington politicians to accomplish anything. So there’s a chance that all of this fury won’t lead to any new legislation. But polls have shown that this is a bipartisan issue–some even suggest that Republicans want regulations on drug prices as much as they want Obamacare repealed. Furthermore, one study showed that drug prices come under pressure when the issue is being debated by politicians.

    Drug regulation could have a profound impact on Valeant. According to an analysis performed last year, Valeant would lose over US$300 million per year if Isuprel and Nitropress prices reverted back to 2014 levels. And neither were even among Valeant’s top six drugs.

    Bigger issues down the line

    Unfortunately for Valeant, new legislation is the least of its worries.

    Remember, the company has faced criticism for its serial acquisitions, steep drug-price hikes, and its relationship with captive pharmacies. Even if there’s no new legislation, none of those tactics will be employed this year. And we’ll get to see Valeant for what it’s really worth.

    So if you think this stock looks cheap, you should tread very carefully and at least wait until next week is over.

    A better stock than Valeant

    Exports of liquefied natural gas could be one of the best growth opportunities out there for long-term investors. And, we think we've identified the Canadian company to invest in. It's a global company with operations across nearly 20 countries and 70 locations. We like it so much, we've named it as 1 Top Stock for 2016 and Beyond. To find out wh
  15. [verwijderd] 20 januari 2016 22:00
    quote:

    Jager63 schreef op 20 januari 2016 21:54:

    Centrale banken gaan zich met de situatie bemoeien. Maak er gebruik van zou ik zeggen. Pak je winst en wegwezen nu het nog kan. Ben bijna van Intercloud af. Om het kwartier gaan er 100 stuks uit voor 0,67 dollar.
    ja winst pakken gaat hem nog niet worden met deze koersen
  16. [verwijderd] 20 januari 2016 22:14
    quote:

    Rolootje schreef op 20 januari 2016 21:56:

    Geen hoop meer voor Intercloud? Lijkt me dat het toch wel goed gaat komen uiteindelijk?
    Even de helft eruit op 0,67. Kan nog genoeg bijkopen eventueel. Verwacht namelijk nog een daling. En niet alleen bij Intercloud, maar over de hele linie!
429 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 22 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
ING 16,040 +0,28 +1,80%
ABN AMRO BANK N.V. 16,055 +0,24 +1,55%
HEIJMANS KON 30,250 +0,45 +1,51%
Aperam 25,560 +0,38 +1,51%
ArcelorMittal 22,810 +0,29 +1,29%
Eurocommercial Properties 22,600 +0,25 +1,12%
JDE PEET'S 16,300 +0,17 +1,05%
CTP 15,760 +0,16 +1,03%
Corbion 23,080 +0,20 +0,87%
CM.COM 5,950 +0,05 +0,85%
Pharming 0,875 +0,01 +0,75%
Wereldhave 14,100 +0,10 +0,71%
SBM Offshore 18,300 +0,10 +0,55%
ADYEN NV 1.514,800 +8,20 +0,54%
RENEWI 9,540 +0,05 +0,53%
Arcadis 55,300 +0,25 +0,45%
SIGNIFY NV 22,820 +0,10 +0,44%
NSI 19,460 +0,08 +0,41%
SHELL PLC 32,170 +0,13 +0,41%
Vopak 44,760 +0,18 +0,40%
Sligro 10,600 +0,04 +0,38%
UNILEVER PLC 54,280 +0,20 +0,37%
VASTNED 27,600 +0,10 +0,36%
Fagron 18,160 +0,06 +0,33%
ALLFUNDS GROUP 5,040 +0,01 +0,30%
IMCD 146,000 +0,30 +0,21%
Basic-Fit 21,640 +0,04 +0,19%
JUST EAT TAKEAWAY 11,795 +0,02 +0,17%
KPN 3,583 +0,00 +0,11%
WDP 19,610 +0,02 +0,10%
Aegon 6,256 +0,00 +0,03%
ASCX 1.248,08 +0,20 +0,02%
ACOMO 17,820 0,00 0,00%
Ahold Delhaize 33,930 0,00 0,00%
Philips Koninklijke 25,490 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
ASML 713,900 -34,20 -4,57%
BESI 139,000 -6,55 -4,50%
Fugro 15,810 -0,54 -3,30%
Wolters Kluwer 169,450 -5,15 -2,95%
EBUSCO HOLDING 0,921 -0,03 -2,94%
ASMI 610,400 -17,80 -2,83%
AZERION 1,532 -0,04 -2,67%
TomTom 5,425 -0,11 -1,99%
Sif Holding 12,120 -0,24 -1,94%
INPOST 15,660 -0,23 -1,45%
AALBERTS NV 33,700 -0,42 -1,23%
Nedap N.V. 58,600 -0,60 -1,01%
NX FILTRATION 2,970 -0,03 -1,00%
OCI 11,420 -0,11 -0,91%
THEON INTERNAT 13,540 -0,12 -0,88%
AMG Critical Materials N.V. 13,090 -0,10 -0,76%
FASTNED 20,200 -0,15 -0,74%
B&S Group SA 4,150 -0,03 -0,72%
EXOR NV 90,050 -0,60 -0,66%
Alfen N.V. 12,755 -0,08 -0,62%
UMG 24,330 -0,15 -0,61%
AEX 908,95 -5,50 -0,60%
TKH 34,880 -0,20 -0,57%
Van Lanschot Kempen NV 46,550 -0,25 -0,53%
Brunel 9,460 -0,05 -0,53%
PostNL 0,936 0,00 -0,48%
Avantium 1,782 -0,01 -0,45%
Galapagos 22,840 -0,10 -0,44%
ASR Nederland 46,680 -0,20 -0,43%
NN Group 43,010 -0,18 -0,42%
Kendrion 10,040 -0,04 -0,40%
ForFarmers 3,285 -0,01 -0,30%
RELX 47,140 -0,14 -0,30%
Heineken 65,640 -0,18 -0,27%
Air France-KLM 7,428 -0,02 -0,27%
Flow Traders 23,740 -0,06 -0,25%
AMX 834,06 -1,72 -0,21%
Akzo Nobel 59,420 -0,12 -0,20%
Accsys 0,538 0,00 -0,19%
DSM FIRMENICH AG 99,000 -0,16 -0,16%
PROSUS 34,910 -0,06 -0,16%
BAM 4,118 0,00 -0,10%
RANDSTAD NV 41,080 -0,02 -0,05%
vlag naam koers verschil relatief verschil
AEX 908,89 -5,56 -0,61%
AEX GR 3.565,06 -21,73 -0,61%
Germany40^ 21.363,40 +109,13 +0,51%
FTSE 100 8.562,11 +16,98 +0,20%
Europe50^ 5.212,48 +6,65 +0,13%
US30^ 44.323,70 +171,10 +0,39%
Nasd100^ 21.786,60 -72,30 -0,33%
US500^ 6.089,53 +2,76 +0,05%
Japan225^ 39.813,90 +10,60 +0,03%
VD-NEW 14,52 -0,08 -0,56%
#/^ Index indications calculated real time, zie disclaimer